Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130.